Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Proto Script Pharmaceutical's Days Sales Outstanding for the
three
months ended in Sep. 2017 was 48.88.
Proto Script Pharmaceutical's Days Inventory for the
three
months ended in Sep. 2017 was 0.
Proto Script Pharmaceutical's Days Payable for the
three
months ended in Sep. 2017 was 379.41.
Therefore, Proto Script Pharmaceutical's Cash Conversion Cycle (CCC) for the
three
months ended in Sep. 2017 was -330.53.
Proto Script Pharmaceutical (OTCPK:PSCR) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Proto Script Pharmaceutical Cash Conversion Cycle Related Terms
Proto Script Pharmaceutical Cash Conversion Cycle Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Proto Script Pharmaceutical Cash Conversion Cycle Chart
PSCR vs EXCC, NXES, PRZM: Cash Conversion Cycle Comparison
For the Specialty Business Services subindustry, Proto Script Pharmaceutical's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Proto Script Pharmaceutical Cash Conversion Cycle vs Business Services Industry
For the Business Services industry and Industrials sector, Proto Script Pharmaceutical's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Proto Script Pharmaceutical's Cash Conversion Cycle falls into.
Proto Script Pharmaceutical Cash Conversion Cycle Calculation
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Proto Script Pharmaceutical's Cash Conversion Cycle for the fiscal year that ended in May. 2016 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Conversion Cycle of -330.53 mean?
Proto Script Pharmaceutical (PSCR) has a Cash Conversion Cycle of -330.53 as of Sep. 2017. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Proto Script Pharmaceutical and its competitors.
Is Proto Script Pharmaceutical's Cash Conversion Cycle too high?
Proto Script Pharmaceutical's current Cash Conversion Cycle is -330.53.
How does Proto Script Pharmaceutical's Cash Conversion Cycle compare to EXCC and NXES?
Proto Script Pharmaceutical's Cash Conversion Cycle of -330.53 can be compared against companies in the Business Services industry. The industry median Cash Conversion Cycle is 38.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Business Services company?
The median Cash Conversion Cycle among Business Services companies is 38.45, based on 1,068 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Proto Script Pharmaceutical and its competitors. For the Business Services industry, the median Cash Conversion Cycle is 38.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Proto Script Pharmaceutical's current Cash Conversion Cycle is -330.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Proto Script Pharmaceutical stock overvalued right now?
Proto Script Pharmaceutical (PSCR) has a current Cash Conversion Cycle of -330.53. The current Cash Conversion Cycle is -330.53. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Proto Script Pharmaceutical (PSCR), the current Cash Conversion Cycle is -330.53 as of Sep. 2017. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Proto Script Pharmaceutical Corp is primarily in the business of repair power wheelchairs and scooters, which are classified as durable medical equipment (DME) products and reimbursable by healthcare insurance providers. It has various contracts with state and governmental insurance providers, among others. These contracts provide the company with the right to sell and repair DME and its health care insurance contracts allow it the ability to service patients nationally. The group currently has its presence of repair facilities in Las Vegas, Nevada, Rancho-Cucamonga, and Anaheim, California.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PSCR has been successfully added to your 
